Review
Copyright ©The Author(s) 2025.
World J Cardiol. Jul 26, 2025; 17(7): 109787
Published online Jul 26, 2025. doi: 10.4330/wjc.v17.i7.109787
Table 4 Analysis of the Association between major prognostic factors and clinical outcomes
Prognostic factors
Clinical impact
Evidence-based basis
Severity level
Management strategies
Timeframe of impact
Population specificity
Intervention efficacy (%)
Ref.
FemaleThe 30-day mortality rate among female patients showed a significant increase (OR = 4.263) Multicenter studies indicate that female patients account for 62.5% of VSR cases and represent an independent risk factorHighClose hemodynamic monitoring with priority given to surgical interventionShort-term (≤ 30 days)Female, Elderly patientsThe surgical survival rate has increased to 70%[7,13,163,164]
Age > 65 years oldThe mortality rate among elderly patients increased significantly (mean age of survival group: 57.4 years vs death group: 72.4 years)Logistic regression analysis showed that age was an independent risk factor for 30-day mortality. (OR = 4.956) HighElderly patients are recommended to delay surgery (if stable) or undergo interventional occlusionShort-term to medium-term (≤ 1 year)Elderly patientsDelayed surgery mortality rate drops to 6.5%[13,165-168]
Killip Class ≥ ⅢThe mortality rate reaches 78.1% in patients with deteriorating cardiac function (death group vs 50% survival group)Killip classification ≥ grade III is significantly associated with 30-day mortality rate. (OR = 24.112) CriticalIABP or VA-ECMO support, early surgical interventionShort-term (≤ 30 days)Merge patients with cardiogenic shockIABP support increases survival rate by 20%[13,20,119,165]
Anterior Wall AMIAnterior wall infarction patients account for 75%-84.6% of VSR cases, with a higher mortality rateAnterior wall infarction is prone to involve the blood supply area of the interventricular septum, increasing the risk of perforation. (P = 0.023) HighEarly screening for VSR, prioritizing PCI or CABG combined with repair surgeryAcute phase to short termPatients with anterior wall AMIPCI reduces mortality rate to 14.3%[13,163,169-171]
VSR Diameter > 15 mmThe mortality rate of patients with large perforations (> 15mm) significantly increasesThe diameter of the perforation is positively correlated with the left-to-right shunt volume, and large perforations require emergency surgerySevereEmergency surgical repair or interventional closureAcute phase (≤ 7 days)Hemodynamically unstable patientThe success rate of the occlusion procedure is 73.8%[13,105,169,172]
Time to VSR Onset ≤ 4 DaysThe 30-day mortality rate reaches 77.4% for patients who develop VSR within 4 days after AMIEarly perforation (≤ 4 days) presents with fragile myocardial tissue and carries high surgical risks. (OR = 12.646) CriticalPostpone surgery until 3-4 weeks later (if stable), supplemented with mechanical circulatory supportShort-term (≤ 30 days)Early-stage perforation patientsDelayed surgery mortality rate 65%[6,13,163]
Elevated Inflammatory MarkersElevated CRP and D-dimer levels are positively correlated with mortality (CRP 85 mg/L in the deceased group vs 27 mg/L in the survival group)Inflammatory response exacerbates myocardial necrosis, and elevated CRP is associated with mortality (P < 0.05) Moderate to HighAnti-inflammatory therapy (such as glucocorticoids), infection controlShort-term to medium-termPatients with concurrent infections or systemic inflammationAnti-inflammatory therapy improves prognosis by 30%[13,166,173]
Cardiogenic Shock (CS)The 30-day mortality rate for patients with combined CS reaches 90%CS is an independent risk factor (OR = 4.288), requiring VA-ECMO supportCriticalVA-ECMO combined with IABP for hemodynamic maintenanceAcute phase (≤ 7 days)Patients with hemodynamic collapseECMO support increases survival rate by 40%[13,21,166,174]
LVEF < 40%Patients with low LVEF showed significantly higher mortality (survivor group LVEF 45% vs deceased group 30%)Left ventricular dysfunction exacerbates shunting, leading to multiple organ failureHighPositive inotropic drugs combined with mechanical support to optimize cardiac function before surgeryMedium-term (≤ 1 year)Patients with chronic heart failurePostoperative survival rate 70%[13,169,175]
No ventricular aneurysmPatients without ventricular aneurysms have a higher mortality rate (OR = 12.646) Ventricular aneurysm may alleviate perforation tension, while non-aneurysmal myocardium is prone to secondary ruptureModerateVentricular aneurysm resection combined with VSR repair surgeryLong-term (> 1 year)Patients with complex anatomical structuresCombined surgery survival rate 85%[163,169,176]
Elevated TnT levelsTnT levels were positively correlated with mortality (3.56 ng/mL in the deceased group vs 0.31 ng/mL in the survival group)Elevated TnT indicates extensive myocardial necrosis and poor prognosis (P = 0.011) HighEarly reperfusion therapy reduces peak TnT levelsAcute phase (≤ 72 hours)Patients with extensive myocardial infarctionReperfusion therapy reduces mortality by 50%[13,165,177,178]
Delayed surgical timingEarly surgery (≤ 7 days) mortality rate 43% vs delayed surgery (> 4 weeks) 6.5%The success rate of surgery is higher after myocardial tissue edema subsidesModerate to HighHemodynamically stable patients are recommended for delayed surgery, supplemented with temporary mechanical supportMid-term (1-4 weeks)Patients with stable conditionDelayed surgery survival rate 935%[179,180]
Multiple coronary artery diseasesThe mortality rate increased in patients with multivessel disease (62.5% vs single-vessel disease)Multiple vessel disease leads to aggravated myocardial ischemia, making repair more difficultHighCABG combined with VSR repair surgeryLong-term (> 1 year)Patients with complex coronary artery lesionsCABG combined surgery survival rate 80%[13,166,181,182]
Anemia (Hb < 10 g/dL) Anemia increases cardiac workload and elevates mortality rates (survivor group Hb 12 g/dL vs deceased group 9 g/dL)Low Hb reduces tissue oxygen supply and accelerates the progression of heart failureModerateBlood transfusion support to maintain Hb > 10 g/dLShort-term to medium-termPatients with chronic kidney disease or bleeding tendencyBlood transfusion improves oxygen delivery with a 25% increase in survival rate[13,99,183]
Renal insufficiencyPostoperative mortality rate increases in patients with renal insufficiency (OR = 1.78) Elevated creatinine levels (> 138.5 μmol/L) are associated with postoperative mortalityHighPreoperative hemofiltration, postoperative CRRT supportShort-term to long-termPatients with chronic kidney diseaseCRRT support reduces mortality rate by 20%[6,13,16]
Elevated Lactate LevelsA lactate level > 4 mmol/L indicates tissue hypoperfusion and is associated with significantly increased mortalityElevated lactate levels reflect systemic hypoperfusion and are associated with multiple organ failure (P < 0.001) CriticalOptimize perfusion (e.g., ECMO), correct metabolic acidosisAcute phase (≤ 24 hours)Patients with shock or sepsisECMO support increases survival rate by 35%[13,166,184,185]
Diabetes MellitusMortality rate increased in patients with combined diabetes (46.9% vs non-diabetic 27.8%)Diabetes accelerate myocardial remodeling and impair healing (P < 0.05) ModerateStrictly control blood glucose (target HbA1c < 7%)Long-term (> 1 year)Diabetic patientsBlood sugar control reduces complication rates by 30%[13,15,186]
Lack of Reperfusion TherapyThe mortality rate reaches 66.7% in patients who did not receive reperfusion therapyReperfusion therapy reduces the incidence of VSR (50% of the survival group received PCI vs 0% in the deceased group)HighEmergency PCI or thrombolysis to restore coronary blood flowAcute phase (≤ 12 hours)AMI patients without contraindicationsPCI reduces mortality rate to 14.3%[13,169,187,188]
Postoperative CAR ≥ 2.83Postoperative CAR is associated with increased risk of complications (OR = 5.540) CAR predicts postoperative infections and organ failure (AUC = 0.767) ModeratePostoperative monitoring of CAR, early anti-infection and nutritional supportShort-term (≤ 30 days)Postoperative patientThe complication rate decreased by 40% after intervention[165,189,190]
Genetic PolymorphismsSpecific genotypes (such as IL-6 variants) are associated with exacerbated inflammatory responsesPreliminary studies suggest that gene polymorphisms influence the efficacy of anti-inflammatory therapy (further verification required)Low to ModeratePersonalized anti-inflammatory regimenLong-term (> 1 year)Genetically susceptible populationResearch phase, no definitive data available yet[191,192]